Skip to main content
Premium Trial:

Request an Annual Quote

RAN, Fluigent Ink Distribution Agreement for Europe

NEW YORK (GenomeWeb) – Fluigent will distribute RAN Biotechnologies' products in Europe, RAN announced today.

RAN is a provider of chemicals for microfluidic and biotech applications, including fluorosurfactants and microfluidic surface coatings for stabilizing water-in-oil emulsions for droplet microfluidics and encapsulating biological molecules, such as DNA, RNA, cells, and proteins. According to the Beverly, Mass.-based firm, droplet microfluidics is an alternative to lab-on-a-chip technology that is compatible with many chemicals and biological molecules.

"Our expertise in synthetic and surface chemistry in general and in surfactants in particular allows us to develop advanced materials for microfluidics," RAN Founder and President Roger Nassar said in a statement. "Partnering with Fluigent is a major step in our exposure efforts in Europe … [and] will help us to reach a wider microfluidic market and allow us to be part of important new technologies by advancing lab-on-a-chip applications."

Fluigent is headquartered in Paris and develops, manufactures, and commercializes microfluidic flow control and fluid handling solutions.

Financial and other terms of the agreement were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.